A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits ...

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from ...

Truist analyst David MacDonald raised the firm’s price target on CVS Health (CVS) to $76 from $60 and keeps a Buy rating on the shares after ...

Shares of CVS Health Corporation (NYSE: CVS) experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's ...

Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in ...

CVS Health Corporation reported financial results for the fourth quarter and full year of 2024, highlighting challenges ...

We recently published a list of These 10 Stocks Led Rally on Wednesday. In this article, we are going to take a look at where CVS Health Corp.

CVS Health downgraded to Hold due to political risks, declining cash flow, and industry battles despite strong Q4 sales and a ...

PBM reform represents a tremendous opportunity. It might be one of the only significant, consequential areas of true ...

CVS Health steered through rising costs in its insurance division to handily beat profit expectations on Wall Street.

Barclays analyst Andrew Mok CFA maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of $73.00. The ...

CVS Health Corp issued an optimistic guidance for 2025 stemming from the expected recovery in its insurance business — ...